IVF

INVO Fertility is a $2.9M micro-cap that the numbers and the filing agree is fighting for survival, not compounding value. Revenue is essentially flat — $6.84M, up just 4.7% YoY — while the FY2025 net loss ballooned to -$23.3M from -$9.26M, a 151.9% deterioration. Gross margin is a threadbare 7.2% and operating margin is -105.8%, so the business loses more than a dollar of operating income for every dollar of sales. Stockholders' equity is negative at -$27.0M against an accumulated deficit the 10-K puts at $91.4M since inception. This is not a growth story with a valuation problem; it is a solvency problem.

The filing is explicit and self-condemning. Management states the accumulated loss 'raises substantial doubt about our ability to continue as a going concern' and — critically — that it does 'not expect our current cash position to be sufficient to fund operations and service our debt for the next 12 months.' With substantial secured indebtedness outstanding, restrictive covenants, and warnings that secured creditors could 'seize and liquidate our assets' on a covenant default, the downside scenario here is a zero for equity holders, not merely a lower multiple. The only stated remedy — further capital raises — is flagged as possibly unavailable 'on acceptable terms, if at all' and as necessarily dilutive.